Lurbinectedin is a chemotherapy drug that is used to treat certain types of cancer. According to the sources provided, it has shown promising results in treating specific types of cancer.

Lurbinectedin has been found to be effective in treating small cell lung cancer (SCLC) [3]. A study conducted by Cancer Network showed that the combination of lurbinectedin and pembrolizumab was safe and effective in relapsed SCLC [3]. The study found that the combination therapy resulted in an overall response rate of 64% [3].

Another study published in the National Center for Biotechnology Information (NCBI) found that lurbinectedin was effective in treating ovarian cancer [2]. The study showed that lurbinectedin was able to inhibit the growth of ovarian cancer cells and increase the survival rate of mice with ovarian cancer [2].

Lurbinectedin has also been found to be effective in treating certain types of sarcomas [2]. The drug has been shown to inhibit the growth of cancer cells in preclinical studies [2].

In conclusion, lurbinectedin has shown promising results in treating specific types of cancer such as small cell lung cancer, ovarian cancer, and certain types of sarcomas. However, further studies are needed to determine the full extent of its effectiveness and potential side effects.

Sources:
[2] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8165873/
[3] https://www.cancernetwork.com/view/preliminary-results-show-second-line-lurbinectedin-plus-pembrolizumab-safe-effective-in-relapsed-sclc
[4] https://www.drugpatentwatch.com/p/tradename/LURBINECTEDIN